ELISA: Direct: To detect hIL-31 (using 100 μL/well antibody solution) a concentration of0.25 - 1.0 μg/mL of this antibody is required. In conjunction with compatible secondaryreagents, it allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-31. Sandwich: To detect hIL-31 (using 100 μL/well antibody solution) a concentration of0.25 - 1.0 μg/mL of this antibody is required. In conjunction with Polyclonal Anti-HumanIL-31 as a capture antibody, it allows the detection of at least 0.2 - 0.4 ng/well ofrecombinant hIL-31. Western blot: To detect hIL-31 this antibody can be used at a concentration of0.1 - 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detectionlimit for recombinant hIL-31 is 1.5 - 3.0 ng/lane, under either reducing or non-reducingconditions. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Reconstitution
Centrifuge vial prior to opening. Restore in sterile PBS containing 0.1 % BSA to a concentration of 0.1 - 1.0 mg/mL.
Buffer
PBS, pH 7.2
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
-20 °C
Stockage commentaire
Store the lyophilized antibody at -20 °C. Following reconstitution it is stable for two weeks at 2 - 8 °C. Frozen aliquots are stable for 6 months when stored at -20 °C.
Date de péremption
6 months
Antigène
IL-31 (IL31)
(Interleukin 31 (IL31))
Autre désignation
Interleukin-31 / IL31
Sujet
Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia and skin lesions, and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.Synonyms: IL-31